Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epinastine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Epinastine Nasal Spray | DRUG | - |
Inclusion Criteria: * A documented history of seasonal allergic rhinitis to mountain cedar pollen Exclusion Criteria: * Significant medical condition * Cardiovascular abnormality * Have a significant physical obstruction in the nose * Started or had a change in immunotherapy within the 30 days pr...
Epinastine is a small molecule being developed for allergic rhinitis and seasonal allergic rhinitis. It is formulated as a nasal spray and is currently in Phase 2 clinical development. The drug is being studied for its effects on symptoms associated with these respiratory conditions.
Epinastine is being developed by Merck & Company, Inc., which is publicly traded under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy for treating allergic rhinitis and seasonal allergic rhinitis.
Epinastine is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing or completed to assess its potential as a treatment for allergic rhinitis and seasonal allergic rhinitis.
Epinastine has been studied in two Phase 2 clinical trials. One trial, NCT00407927, evaluated epinastine nasal spray in 571 subjects with seasonal allergic rhinitis in the United States. Another trial, NCT01382654, compared two formulations of epinastine nasal spray against azelastine nasal solution in 131 adults with allergic rhinitis.
No, Epinastine is not the same as azelastine. Epinastine is an investigational nasal spray being developed by Merck, while azelastine is a separate medication used as a comparator in clinical trials. They are distinct chemical entities with different mechanisms of action.